Publications by authors named "Nolan Wages"

Claim this Profile
I
Improvements in Real-World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment.
Thuy N Ho, Patrick Willard, Graeme F Murray, Li Liu, Nolan Wages

Eur J Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel-induced neuroinflammation after systemic administration in male and female mice.
Martial Caillaud, Yogesh Rakholia, Lauren Soleo, Bryan D Mckiver, Wisam Toma, Nolan A Wages

J Pain· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-finding designs for cell therapy cancer clinical trials evaluating drug-combinations.
Evan M Bagley, Nolan A Wages

Contemp Clin Trials· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TODO: A Triple-Outcome Double-Criterion Optimal Design for Dose Monitoring-and-Optimization in Multi-Dose Randomized Trials.
Jingyi Zhang, Heng Zhou, Nolan A Wages, Zifang Guo, Fang Liu

Stat Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the Role of Patient-Reported Outcomes for Decision-Making in Early-Phase Dose-Finding Clinical Trials.
Richard Brown, Nolan A Wages, Li Liu, Arnethea L Sutton, Andrew S Poklepovic

Curr Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity Attribution.
Nolan A Wages, Bethany J Horton, Li Liu, Enrica Marchi, Gina R Petroni

Cancers (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia.
Graeme F Murray, Ian M Bouligny, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan A Wages

Eur J Haematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer.
Remziye E Wessel, Nardin Ageeb, Joseph M Obeid, Ileana S Mauldin, Kate A Goundry, Nolan A Wages

J Immunother Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applications of the partial-order continual reassessment method in the early development of treatment combinations.
Nolan A Wages, Patrick M Dillon, Craig A Portell, Craig L Slingluff, Gina R Petroni

Clin Trials· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus.
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung

Clin Trials· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer.
Remziye E Wessel, Nardin Ageeb, Joseph M Obeid, Ileana Mauldin, Kate A Goundry, Nolan A Wages

bioRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-finding based on feasibility and late-onset toxicity in adoptive cell therapy trials.
Evan M Bagley, Nolan A Wages

J Biopharm Stat· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer.
Trish Millard, Christiana Brenin, Clare Humphrey, Ajay Dhakal, Carla Falkson, Nolan A Wages

Int J Breast Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia.
Ian M Bouligny, Graeme Murray, Michael Doyel, Tilak Patel, Josh Boron, Nolan A Wages

Med Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isotonic Phase I cancer clinical trial design utilizing patient-reported outcomes.
Nolan A Wages, Ruitao Lin

Stat Biopharm Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
Ian M Bouligny, Graeme Murray, Thuy Ho, Michael Doyel, Tilak Patel, Nolan A Wages

Leuk Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local continual reassessment methods for dose finding and optimization in drug-combination trials.
Jingyi Zhang, Fangrong Yan, Nolan A Wages, Ruitao Lin

Stat Methods Med Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia.
Ian M Bouligny, Graeme Murray, Thuy Ho, Michael Doyel, Tilak Patel, Nolan A Wages

Res Sq· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer.
Nolan A Wages, Bailey Nelson, Jordan Kharofa, Teresa Meier

Int J Biostat· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isotonic design for phase I cancer clinical trials with late-onset toxicities.
Nolan A Wages, Thomas M Braun, Mark R Conaway

J Biopharm Stat· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia.
Ian M Bouligny, Graeme Murray, Michael Doyel, Tilak Patel, Josh Boron, Nolan A Wages

EJHaem· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent dose-finding of a novel cancer drug with and without a second agent.
Nolan A Wages, Ramy R Saleh, Thomas M Braun

J Clin Transl Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the relationship between vaginal apex "dog ears" and patterns of recurrence in endometrial cancer following adjuvant image guided vaginal cuff brachytherapy.
Emily K Venner, Kristin A Ward, Nolan A Wages, Bryant Walker, Bruce P Libby

Brachytherapy· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
Nathaniel S O'Connell, Nolan A Wages, Elizabeth Garrett-Mayer

Contemp Clin Trials· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SEMIPARAMETRIC DOSE FINDING METHODS FOR PARTIALLY ORDERED DRUG COMBINATIONS.
Matthieu Clertant, Nolan A Wages, John O'Quigley

Stat Sin· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis